Felix Baker

Felix Baker discloses dealings in 3 companies, chiefly Seagen Inc., Genomic Health Inc and Alexion Pharmaceuticals Inc. The record holds 228 filings, for trades running from 1 January 2016 to 1 January 2017.

Purchases make up the whole of the open-market record (186 purchases, €286.0M). The amount is not disclosed for 4 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 34 share grants and 8 option exercises.

Half of the purchases are above €370k and half below. Clusters matter here: 24 out of 142 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 4 January 2017: a share grant of €19k, in Genomic Health Inc. The most recent open-market purchase was published on 9 November 2016, 3,636 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.